SIStockInvestingSI.com

NASDAQ · VTRS · Drug Manufacturers - Specialty & Generic

Viatris Inc. (VTRS) stock analysis

$18.45−1.07%Data as of Oct 21, 2026
  • VTRS gained 7.4% over the past month versus 0.0% for the S&P 500, ranking 110th of 497 S&P 500 stocks.
  • Over 12 months it returned +82.6%, 66.8 points ahead of the S&P 500, and trades 1.1% below its 52-week high.
  • In the last 30 days 2 analysts raised earnings estimates and 0 cut; forward EPS moved +0.8% (+0.7% over 90 days).
  • It sits in the Generics & established medicines segment of the Healthcare Value Chain, where the 1-month median return is +7.4%.
  • The daily chart reads Intermediate uptrend · Upside breakout (since Oct 21, 2026).
Market cap$21.2B
12-month return+82.6%
Forward P/E6.9×
Mean target vs price+1.8%

One-year price with 50- and 200-day averages

Open in Hub
10.212.815.417.9JanAprJulOct
18.4550-day200-day

Performance vs the market

Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.

VTRS+7.4%
Sector median−8.7%
S&P 5000.0%
VTRS+6.8%
Sector median−5.4%
S&P 500+4.7%
VTRS+27.1%
Sector median−1.5%
S&P 500+8.7%
VTRS+82.6%
Sector median+1.7%
S&P 500+15.8%
1-month rank in the S&P 500110 / 497
3-month rank in its sector · Healthcare236 / 720

Chart structure

Read by our daily-bar structure engine from swing highs, swing lows and moving averages.

Intermediate uptrend · Upside breakoutAwaiting confirmation

Holding since Oct 21, 2026

  • Close above EMA20 above EMA50
  • EMA50 rose over the last ten sessions
This pattern on this stock

32 occurrences in 10 years. The median move over the next 20 sessions was −0.8%, positive 44% of the time, against 0.0% for any day in the same period.

Reference zone, stop and targets for this structureSee the trade plan in Hub ↗

Analyst earnings revisions

Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.

Forward EPS$2.68
30-day change+0.8%
90-day change+0.7%
Mean target$18.78 +1.8%
Raised (30d) 2Cut (30d) 0

9 analysts cover the stock

Where it sits in the supply chain

Healthcare Value Chain · Drugs & devices

Explore the full chain map in Hub
Its segment
Generics & established medicines+7.4%
VTRS+7.4%1 month

Established and generic medicines depend on pricing, compliance and product mix.

Sells into
Drug distribution+13.9%
MCK+13.9%1 monthCOR+8.3%1 monthCAH+16.2%1 month

Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps

Risk profile

Max drawdown, 12M−19.0%
Volatility, 60D27.3%
From 52-week high−1.1%
From 52-week low+86.2%
Forward P/E6.9×

Themes

  • Gene/Cell Therapy3M rank 38 / 99
MCKMcKessonCORCencora, Inc.CAHCardinal Health, Inc.ZTSZoetis Inc.LLYEli LillyJNJJohnson & JohnsonABBVAbbVieUNHUnitedHealth Group

Track this stock every day

Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.

Open in Hub ↗